Arbutus Biopharma Corporation Common Stock — Rendiconto Finanziario Trimestrale (NASDAQ:ABUS)

Apri il grafico completo Full chart

Financials

Panoramica Estratto Conto Statistiche

Trimestrale Annuale

Market Capitalization 900.77 M
Employee 19
Founded 2007
CEO William H. Collier
Website www.arbutusbio.com
Headquarter British Columbia, Canada
FIGI BBG000RR8V85
Industry Biotecnologia

Ricavi totali

Utile netto

Utile base per azione (EPS base)

Debito totale

Liquidità libera

Disponibilità liquide e mezzi equivalenti

Rapporto prezzo/utili

5.42

Rapporto prezzo/fatturato

4.58

Arbutus Biopharma Corporation - Common Stock

Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection. It is headquartered in Warminster, Pennsylvania. The company was formerly known as Tekmira, which was spun out of Inex Pharmaceuticals in 2007.

ABUS

Financials

Arbutus Biopharma Corporation - Common Stock

Notizie

Gli EPS di Arbutus Biopharma hanno battuto le aspettative per 0,91$, il fatturato supera le previsioni

Arbutus Biopharma: A Fascinating HBV Story, But Still Too Early (NASDAQ:ABUS)

Moderna's Revenues See Strong International Momentum in Q1 Earnings

Moderna's Quarterly Earnings Preview: What You Need to Know

Gli EPS di Arbutus Biopharma hanno battuto le aspettative per 0,02$, il fatturato supera le previsioni

Le azioni di Roivant Sciences raggiungono il massimo storico a 30,31 USD

Moderna reaches $950 million settlement with Arbutus and Genevant over patent litigation

Why Moderna’s $950M Patent Bill Is A Small Price For Pipeline Freedom (NASDAQ:MRNA)

Chardan conferma il rating su Arbutus Biopharma dopo l’accordo con Moderna

Chardan reiterates Arbutus Biopharma stock rating on Moderna deal

MRNA Stock Gains on $2.25B Deal to Settle Patent Dispute With ROIV, ABUS

Moderna rises as up to $2.25 billion settlement for COVID vaccine patent dispute to remove overhang